PPT-Antiplatelet Therapy for Secondary Prevention in the First Year Following

Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group JeanFrançois Tanguay MD CSPQ FRCPC FACC FAHA FESC Michael P Love MB ChB MD MRCP and Robert C Welsh MD FRCP FACC. Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . GRACE. . 5-Year Mortality . Antiplatelet Therapy. Cornerstone of Medical Therapy Post ACS. TRA 2P-TIMI 50. Efficacy/Safety. ATLAS ACS 2—TIMI 51. Study Design. ATLAS-2. . Baseline Patient Characteristics. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Primary Prevention ASCVD. Jennifer Bannon RN BSN MSHI. Table of Contents. Objectives . Cardiovascular Disease. Cardiovascular Disease (2). ABCS-Aspirin when appropriate. Anatomy of a Performance Measure. Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts.